On October 17, Kexing Biopharm (688136.SH) announced that its partner Zhejiang Haichang Biomedical Technology Co., Ltd. recently received approval from the United Kingdom Medicines and Healthcare Products Regulatory Agency for the company's introduction of the injectable paclitaxel (albumin-bound) (Apexelsin, referred to as "albumin paclitaxel") market authorization.
The injectable paclitaxel (albumin-bound) formulation has clinical advantages over conventional paclitaxel injections and paclitaxel liposomes, with improved safety and patient compliance. It has high clinical acceptance and plays an indispensable clinical role in the field of cancer treatment.